Home
Despite David Cameron’s promise in 2010 to end the “revolving door” between Whitehall and the private sector, the recently ennobled Tory peer has declared work as an adviser to Roche, the Swiss drugs company, and as an adviser to private equity firm Blackstone on investments in the health sector.
Analysis Cancer Drugs Fund seems to help pharmaceuticals giant Roche most. As Nice rejects breast cancer drug Kadcyla over cost, how Swiss firm has benefited from fund it played key role in establishing
Roche has been one of the biggest beneficiaries of the cancer drugs fund that Lansley set up in 2010 to pay for life-extending medicines that were considered too expensive by the NHS.
His work involves advising on “pharmaceutical supply and pricing issues in Europe” until the end of November, according to his House of Lords register of interests.
A controversy broke out in September when it emerged that the company’s breast cancer drug, Kadcyla, was to be dropped by the fund because of the £90,000 per patient per year price – although Roche claimed it was closer to £70,000. A deal has since been struck to bring the cost down to £60,000, allowing it to remain on the fund’s list.
Lansley, who is considered the architect of the coalition’s controversial NHS changes that critics say have led to greater privatisation, is also giving “advice on industry” to Blackstone, which was criticised for its previous ownership of Southern Cross care homes, which failed under a mountain of debt in 2011 five years after being sold by the company.
More on this latest story here http://www.theguardian.com/politics/2015/nov/16/andrew-lansley-three-more-advisory-jobs-drugs-firm
Analysis Cancer Drugs Fund seems to help pharmaceuticals giant Roche most. As Nice rejects breast cancer drug Kadcyla over cost, how Swiss firm has benefited from fund it played key role in establishing
Roche has been one of the biggest beneficiaries of the cancer drugs fund that Lansley set up in 2010 to pay for life-extending medicines that were considered too expensive by the NHS.
His work involves advising on “pharmaceutical supply and pricing issues in Europe” until the end of November, according to his House of Lords register of interests.
A controversy broke out in September when it emerged that the company’s breast cancer drug, Kadcyla, was to be dropped by the fund because of the £90,000 per patient per year price – although Roche claimed it was closer to £70,000. A deal has since been struck to bring the cost down to £60,000, allowing it to remain on the fund’s list.
Lansley, who is considered the architect of the coalition’s controversial NHS changes that critics say have led to greater privatisation, is also giving “advice on industry” to Blackstone, which was criticised for its previous ownership of Southern Cross care homes, which failed under a mountain of debt in 2011 five years after being sold by the company.
More on this latest story here http://www.theguardian.com/politics/2015/nov/16/andrew-lansley-three-more-advisory-jobs-drugs-firm
